InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $13.050 7.02 (116.42%)+
Announcement
Release
13 Nov 2025 9:24AM
Price at Release
$6.030
Full Release
download
Summary
Anteris Technologies Ltd reported its quarterly results, highlighting its continued focus on developing the DurAVR® Transcatheter Heart Valve (THV) for treating aortic stenosis. The company raised $80 million through an IPO to support this initiative. Significant expenses were incurred in research and development as well as general and administrative areas, contributing to a reported net loss. The FDA approved the commencement of the PARADIGM Trial to further evaluate the DurAVR® THV. Financial statements revealed a reduction in cash reserves to $9.1 million by the end of September 2025.
Key Points
  • Anteris Technologies Global Corp. is a structural heart company focused on developing medical devices for heart conditions such as aortic stenosis.
  • The company’s lead product is the DurAVR® Transcatheter Heart Valve (THV), designed to mimic a healthy human aortic valve.
  • The DurAVR® THV uses ADAPT® tissue technology for anti-calcification, and has been FDA-clearance for clinical use worldwide.
  • Anteris raised net proceeds of $80.0 million from its initial public offering, primarily for the development of DurAVR® THV.
  • Third quarter results showed a net loss of $22,209 thousand, with significant investments in R&D and administrative expenses.
  • During the quarter, $52.7 million was allocated to the development of the DurAVR® THV and the PARADIGM Trial preparations.
  • The PARADIGM Trial received FDA approval to proceed in November 2025 for evaluating the DurAVR® THV.
  • The company reported a decrease in cash reserves, with $9,119 thousand in cash and equivalents as of September 30, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.